SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-250984
Filing Date
2024-11-05
Accepted
2024-11-05 07:41:59
Documents
15
Period of Report
2024-11-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d906207d8k.htm   iXBRL 8-K 25521
2 EX-99.1 d906207dex991.htm EX-99.1 110280
6 GRAPHIC g906207g1105071321871.jpg GRAPHIC 3772
  Complete submission text file 0001193125-24-250984.txt   280681

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kpti-20241105.xsd EX-101.SCH 2847
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20241105_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20241105_pre.xml EX-101.PRE 11259
17 EXTRACTED XBRL INSTANCE DOCUMENT d906207d8k_htm.xml XML 3628
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

IRS No.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 241425648
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)